文献速递胸部肿瘤乳腺癌消化系统肿瘤

2018年和2040年全球化疗需求及相应医生人力需求的估算:一项基于人群的研究

Estimates of global chemotherapy demands and corresponding physician workforce requirements for 2018 and 2040: a population-based study.
PubMed 文献 · Lancet Oncol · 2019-05-08

基于GLOBOCAN 2018的29种癌症发病率数据,结合指南最佳化疗利用比例,估算2018至2040年需首次化疗的患者数及相应肿瘤医生人力需求。需首次化疗患者将从2018年978万增至2040年1498万,相对增加53%;

要点

  • 需首次化疗患者将从2018年978万增至2040年1498万,相对增加53%。
  • 中低收入国家患者占比从2018年63%(6162240/9782783)升至2040年67%(10071049/14984560)。
  • 2040年最常见化疗适应证为肺癌(2455137/14984560,16.4%)、乳腺癌(1898740,12.7%)和结直肠癌(1678153,11.1%)。

核心结论

  • 需要在化疗服务提供和肿瘤医生方面进行战略性投入,以满足2040年预计增加的化疗需求。

研究设计与样本

  • 基于GLOBOCAN 2018中183个国家29种癌症2018年发病率及2040年预测数据的人群研究。
  • 将指南中最佳化疗利用比例应用于发病率数据,生成2018年和2040年需首次化疗的新患者数。
  • 按每名医生每年接诊150例需化疗新患者估算所需肿瘤医生数,并做每名医生每年100例或300例的敏感性分析。
  • 对就诊时癌症分期如何影响化疗需求进行了敏感性分析。

主要发现

  • 2018年至2040年,每年需首次化疗的患者将从978万增至1498万,相对增加53%。
  • 需化疗患者中居住在中低收入国家的比例2018年为63%(6162240/9782783),2040年将为67%(10071049/14984560)。
  • 2040年全球最常见化疗适应证为肺癌(2455137/14984560,16.4%)、乳腺癌(1898740,12.7%)和结直肠癌(1678153,11.1%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The incidence of cancer (excluding non-melanomatous skin cancers) is projected to rise from 17·0 million to 26·0 million between 2018 and 2040. A large proportion of these patients would be likely to derive benefit from chemotherapy, but no studies so far have quantified current and projected global chemotherapy demands. We aimed to estimate changes in national, regional, and global demands for first-course chemotherapy and the cancer physician workforce between 2018 and 2040 if all patients were treated according to best-practice evidence-based guidelines. METHODS: Data for the incidence of 29 types of cancer in 183 countries in 2018, and projections of incidence in 2040, were obtained from GLOBOCAN 2018. Optimal chemotherapy utilisation from evidence-based guidelines was applied to these incidence data to generate the number of new patients requiring first-course chemotherapy in 2018 and 2040. We then estimated the corresponding cancer physician workforce required to deliver this chemotherapy (on the basis of physicians seeing 150 new patients requiring chemotherapy per year). We did sensitivity analyses to investigate how cancer stage at presentation affected chemotherapy demands. We also did sensitivity analyses to explore changes to workforce requirements if each physician was seeing 100 new patients requiring chemotherapy per year or 300 new patients requiring chemotherapy per year. FINDINGS: Between 2018 and 2040, the number of patients requiring first-course chemotherapy annually will increase from 9·8 million to 15·0 million, a relative increase of 53%. The estimated proportion of patients needing chemotherapy who reside in low-income or middle-income countries was 63% (6 162 240 of 9 782 783) in 2018, and will be 67% (10 071 049 of 14 984 560) in 2040. The most common indications for chemotherapy worldwide in 2040 will be lung cancer (accounting for 2 455 137 [16·4%] of 14 984 560 cases eligible for chemotherapy), breast cancer (1 898 740 [12·7%]), and colorectal cancer (1 678 153 [11·1%]). We estimated that, in 2018, 65 000 cancer physicians were required worldwide to deliver optimal chemotherapy-a figure that we estimate will rise to 100 000 by 2040 (with estimates ranging from from 50 000 to 150 000, depending on workload). INTERPRETATION: Strategic investments in chemotherapy service provision and cancer physicians are needed to meet the projected increased demand for chemotherapy in 2040. FUNDING: None.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Wilson BE, Jacob S, Yap ML, et al. Estimates of global chemotherapy demands and corresponding physician workforce requirements for 2018 and 2040: a population-based study. Lancet Oncol. 2019. PMID: 31078462. doi:10.1016/S1470-2045(19)30163-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。